IN2012DN03128A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03128A
IN2012DN03128A IN3128DEN2012A IN2012DN03128A IN 2012DN03128 A IN2012DN03128 A IN 2012DN03128A IN 3128DEN2012 A IN3128DEN2012 A IN 3128DEN2012A IN 2012DN03128 A IN2012DN03128 A IN 2012DN03128A
Authority
IN
India
Prior art keywords
compositions
eye
active ingredient
treatment
group
Prior art date
Application number
Inventor
Bastian Theisinger
Sonja Theisinger
Bernhard Gunther
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41731659&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN03128(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of IN2012DN03128A publication Critical patent/IN2012DN03128A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides novel pharmaceutical compositions for the treatment of keratoconjunctivitis sicca comprising liquid vehicles which include one or more semifluorinated alkanes. The compositions incorporate an active ingredient selected from the group of macrolide immunosuppressants. They can be administered topically into the eye. The invention further provides kits comprising such compositions.
IN3128DEN2012 2009-12-14 2010-12-13 IN2012DN03128A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09015423A EP2335735A1 (en) 2009-12-14 2009-12-14 Pharmaceutical composition for treatment of dry eye syndrome
PCT/EP2010/069495 WO2011073134A1 (en) 2009-12-14 2010-12-13 Pharmaceutical composition for treatment of dry eye syndrome

Publications (1)

Publication Number Publication Date
IN2012DN03128A true IN2012DN03128A (en) 2015-09-18

Family

ID=41731659

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3128DEN2012 IN2012DN03128A (en) 2009-12-14 2010-12-13

Country Status (15)

Country Link
US (1) US8614178B2 (en)
EP (2) EP2335735A1 (en)
JP (5) JP5663595B2 (en)
KR (2) KR101722039B1 (en)
CN (1) CN102652022B (en)
AU (1) AU2010333039B2 (en)
BR (3) BR122020020872B1 (en)
CA (2) CA2776860C (en)
DK (1) DK2512515T3 (en)
ES (1) ES2449308T3 (en)
IN (1) IN2012DN03128A (en)
MX (1) MX2012006720A (en)
PL (1) PL2512515T3 (en)
PT (1) PT2512515E (en)
WO (1) WO2011073134A1 (en)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2437684B1 (en) 2009-06-03 2022-06-15 ForSight Vision5, Inc. Anterior segment drug delivery
WO2011113855A2 (en) 2010-03-17 2011-09-22 Novaliq Gmbh Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
CN107397718A (en) 2011-05-25 2017-11-28 诺瓦利克有限责任公司 Externally-applied medicinal composition based on semifluorinated alkane class
KR101773648B1 (en) 2011-05-25 2017-08-31 노바리크 게엠베하 Pharmaceutical composition for administration to nails
KR101989648B1 (en) 2012-01-23 2019-06-14 노바리크 게엠베하 Stabilised protein compositions based on semifluorinated alkanes
DK3181119T3 (en) 2012-09-12 2019-09-16 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS TO USE IN TREATMENT OF KERATOCONJUNCTIVITIS SICCA
CN113679697A (en) * 2012-09-12 2021-11-23 诺瓦利克有限责任公司 Compositions comprising mixtures of semifluorinated alkanes
TR201812013T4 (en) 2012-09-12 2018-09-21 Novaliq Gmbh EYE WASHING COMPOSITIONS.
EP2730291A1 (en) * 2012-11-09 2014-05-14 Fluoron Gmbh Internal Tamponade Composition
WO2014117035A1 (en) 2013-01-24 2014-07-31 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS
JP6304475B2 (en) * 2013-01-31 2018-04-04 ロート製薬株式会社 Eye drops
ES2799185T3 (en) * 2013-03-13 2020-12-15 Santen Pharmaceutical Co Ltd Therapeutic agent for meibomian dysfunction
BR112016001522B1 (en) 2013-07-23 2019-10-01 Novaliq Gmbh STABILIZED ANTIBODY COMPOSITIONS
CA2927321A1 (en) * 2013-10-15 2015-04-23 Forsight Vision5, Inc. Formulations and methods for increasing or reducing mucus
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
WO2017058774A1 (en) * 2015-09-29 2017-04-06 The Regents Of The University Of California Methods of diagnosing diseases of mucosal surfaces
MX2018003781A (en) 2015-09-30 2018-09-12 Novaliq Gmbh Semifluorinated compounds for ophthalmic administration.
CN108348777B (en) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 Semifluorinated compounds and compositions thereof
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (en) * 2016-09-22 2024-05-22 Novaliq Gmbh Pharmaceutical compositions for use in the therapy of blepharitis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
AU2017333420A1 (en) * 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
EP3558308A1 (en) * 2016-12-22 2019-10-30 Novaliq GmbH Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
PT3399962T (en) * 2016-12-23 2020-09-03 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
JP7108631B2 (en) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． Anhydrous compositions of mTOR inhibitors and methods of use thereof
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
US10717691B2 (en) 2017-05-05 2020-07-21 Novaliq Gmbh Process for the production of semifluorinated alkanes
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
KR20200059272A (en) 2017-09-27 2020-05-28 노바리크 게엠베하 Ophthalmic composition comprising latanoprost for use in the treatment of ocular diseases
CN111182893A (en) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 Ophthalmic composition comprising F6H8
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (en) 2018-03-28 2025-11-07 노바리크 게엠베하 Pharmaceutical composition containing timolol
JP2021522219A (en) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー Ophthalmic composition containing tafluprost for the treatment of glaucoma
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
EP3852734A1 (en) * 2018-09-22 2021-07-28 Novaliq GmbH Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
WO2020064549A1 (en) 2018-09-27 2020-04-02 Novaliq Gmbh Lipid barrier repair
SG11202102820VA (en) * 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
US20220008397A1 (en) * 2019-01-21 2022-01-13 Novaliq Gmbh Pharmaceutical composition for the treatment of ocular neovascularisation
CN113710228A (en) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 Compositions and methods for treating ocular neovascularization
CN114126580A (en) 2019-05-24 2022-03-01 诺瓦利克有限责任公司 Ophthalmic composition for treating ocular allergies
US12419933B2 (en) 2019-09-06 2025-09-23 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis
WO2021048803A1 (en) 2019-09-13 2021-03-18 Minas Coroneo Eye drop dispenser
WO2021191273A1 (en) 2020-03-24 2021-09-30 Hovione Scientia Limited Compositions for use in treating meibomian gland dysfunction
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
CN120916776A (en) * 2023-02-13 2025-11-07 诺瓦利克有限责任公司 Ophthalmic composition for ocular surgical preparation of patients with ocular surface diseases
AU2023270196B2 (en) * 2023-11-20 2025-06-26 Dyer, Gordon Wayne DR Method of Arthropod Egress

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
KR920003601B1 (en) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 Composition of Eye Drop Cyclosporin
US5874481A (en) * 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
DE19536504C2 (en) 1995-09-29 1999-09-23 H Meinert Use of fluorinated alkanes
DE19861012A1 (en) * 1998-03-18 1999-09-30 Pharm Pur Gmbh Ophthalmological use of fluorocarbon with low dissolved oxygen content, e.g. for treating ischemic retinal disease
AU777915B2 (en) * 1999-04-30 2004-11-04 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
DE19938668B4 (en) * 1999-08-14 2006-01-26 Bausch & Lomb Inc. Artificial tears
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
WO2005099718A1 (en) * 2004-04-19 2005-10-27 Centre National De La Recherche Scientifique (C.N.R.S.) Lung surfactant supplements
JP2008501806A (en) * 2004-06-08 2008-01-24 オキュラリス ファーマ， インコーポレイテッド Hydrophobic ophthalmic composition and method of use
DE102007055046A1 (en) * 2007-11-19 2009-05-28 Fluoron Gmbh infusion
EP2110126B9 (en) 2008-04-18 2012-09-19 Novaliq GmbH Inhalative and instillative use of semi-fluorised alkanes as active ingredient carriers in the intrapulmonary area

Also Published As

Publication number Publication date
AU2010333039B2 (en) 2014-08-28
JP2017078086A (en) 2017-04-27
CN102652022B (en) 2014-12-17
WO2011073134A1 (en) 2011-06-23
BR122017018955B1 (en) 2022-03-08
BR122020020872B1 (en) 2021-09-08
JP2015028064A (en) 2015-02-12
JP2019006803A (en) 2019-01-17
EP2335735A1 (en) 2011-06-22
CA2776860A1 (en) 2011-06-23
CA2776860C (en) 2016-10-25
JP2019070003A (en) 2019-05-09
JP6731039B2 (en) 2020-07-29
JP2013513586A (en) 2013-04-22
KR20120115977A (en) 2012-10-19
JP6397472B2 (en) 2018-09-26
JP5663595B2 (en) 2015-02-04
HK1172269A1 (en) 2013-04-19
CN102652022A (en) 2012-08-29
KR101722039B1 (en) 2017-03-31
BR112012014190A2 (en) 2016-05-31
BR112012014190B8 (en) 2021-05-25
BR112012014190B1 (en) 2021-03-02
JP6096731B2 (en) 2017-03-15
PL2512515T3 (en) 2014-05-30
MX2012006720A (en) 2012-07-30
CA2941956A1 (en) 2011-06-23
KR101652714B1 (en) 2016-09-01
KR20160105533A (en) 2016-09-06
US20120244177A1 (en) 2012-09-27
CA2941956C (en) 2018-09-04
AU2010333039A1 (en) 2012-07-12
DK2512515T3 (en) 2014-03-10
ES2449308T3 (en) 2014-03-19
PT2512515E (en) 2014-03-04
US8614178B2 (en) 2013-12-24
EP2512515A1 (en) 2012-10-24
EP2512515B1 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
IN2012DN03128A (en)
MX389597B (en) Pyridopyrimdinone cdk2/4/6 inhibitors
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MY175800A (en) Combination treatment of cancer
EP4342540A3 (en) Substituted heterocyclyl derivatives as cdk inhibitors
EP4292662A3 (en) Substituted indole mcl-1 inhibitors
WO2015070224A3 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
MX2016011468A (en) Human plasma kallikrein inhibitors.
MX2013012776A (en) Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors.
BR112014000792A2 (en) Piperidinyl Compounds for Use as Tanquirase Inhibitors
EP4342537A3 (en) Semifluorinated alkane compositions
CL2012001714A1 (en) Compounds derived from pyrrole [3,4-b] pyridin-5-one, inhibitors of pi3k; pharmaceutical composition comprising them; and use for the treatment of diseases such as Alzheimer's, epilepsy, multiple sclerosis, Parkinson's, among others.
WO2012027065A3 (en) Combination therapy for treatment of disease
DOP2019000275A (en) NEW BICYCLIC PIRAZOLE DERIVATIVES
EP4414376A3 (en) Novel depsipeptide and uses thereof
EP4403552A3 (en) C-terminal hsp90-inhibitors
EP3216798A3 (en) Ketolide compounds
MX341220B (en) Tamarind seed polysaccharide for use in the treatment of microbial infections.
PH12013500644A1 (en) Co-crystals and salts of ccr3-inhibitors
CL2012003521A1 (en) Piperidino derivative (r) -n - ((r) -1 - ((3s-4s) -4- (4-chlorophenyl) -3,4-dihydroxy-3-methylpiperidin-1-yl) -3-methyl-1 -oxobutan-2-yl) -3,3-difluorocyclopentanecarboxamide, chemokine receptor modulator; pharmaceutical composition; and use of the compound and its composition in inflammatory and autoimmune diseases, among others.
MX2024010625A (en) Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof.
MX2020012989A (en) Therapeutic agent for fibrosis.
IN2014CN02908A (en)
MX2017015961A (en) Muscarinic m1 receptor positive allosteric modulators.
NZ740587A (en) Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators